Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Blood (2024) 144 (Supplement 1): 5188.

https://doi.org/10.1182/blood-2024-205427

Published: 2024

Journal Articles

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Alfonso Piciocchi, Monica Messina, Giovanni Marsili, Marta Cipriani, Francesca Paola Paoloni, Davide Lazzarotto, Anna Candoni, Alessandro Rambaldi, Matteo Leoncin, Paola Fazi, Marco Vignetti, Robin Foà, Sabina Chiaretti

Blood (2024) 144 (Supplement 1): 274.

https://doi.org/10.1182/blood-2024-200643

Published: 2024

Journal Articles

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Blood (2024) 144 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2024-210315

Published: 2024

Journal Articles

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Marco Cerrano, Lazzarotto Davide, Eleonora Boscaro, Erika Borlenghi, Ilaria Tanasi, Patrizia Chiusolo, Paola Minetto, Francesco Grimaldi, Michelina Dargenio, Matteo Leoncin, Silvia Trappolini, Cristina Papayannidis, Fabio Forghieri, Carmela Gurrieri, Patrizia Zappasodi, Roberta La Starza, Nicola Fracchiolla, Federica Di Biase, Maria Ilaria Del Principe, Marzia Defina, Crescenza Pasciolla, Benedetta Cambò, Federico Mosna, Daniela Pietrasanta, Sabrina Mariani, Valentina Mancini, Fabio Guolo, Federico Lussana, Elisabetta Todisco, Mario Annunziata, Valeria Calafiore, Maria Ciccone, Matteo Piccini, Matteo Emidio Dragani, Beatrice Sani, Endri Mauro, Claudia Basilico, Beatrice De Marco, Marco Antonacci, Laura Forlani, Monica Fumagalli, Fabio Trastulli, Monia Lunghi, Prassede Salutari, Sara Mastaglio, Sabina Chiaretti, Anna Candoni, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Massimiliano Bonifacio

Blood (2024) 144 (Supplement 1): 113.

https://doi.org/10.1182/blood-2024-206854

Published: 2024

Journal Articles

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Blood (2024) 144 (5): 541–551.

https://doi.org/10.1182/blood.2023023625

Published: 2024

Includes: Supplemental data

Journal Articles

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Blood (2023) 142 (Supplement 1): 826.

https://doi.org/10.1182/blood-2023-174973

Published: 2023

Journal Articles

Impact of COVID-19 in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Possible Role of the Association to Anti-CD20 Antibody? a Multicentre Seifem Study

Blood (2023) 142 (Supplement 1): 3283.

https://doi.org/10.1182/blood-2023-180955

Published: 2023

Journal Articles

Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)

Blood (2023) 142 (Supplement 1): 2948.

https://doi.org/10.1182/blood-2023-184851

Published: 2023

Journal Articles

Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study

Blood (2023) 142 (Supplement 1): 6529.

https://doi.org/10.1182/blood-2023-181037

Published: 2023

Journal Articles

Gimema Seifem Real-Life Study VS Randomized CPX-351 Registrative Trial for Older Patients with Secondary ACUTE Myeloid Leukemia: An Unanchored Matching-Adjusted Indirect Comparison of Infection Rates and Survival Outcomes

Blood (2023) 142 (Supplement 1): 5845.

https://doi.org/10.1182/blood-2023-189358

Published: 2023

Journal Articles

Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol

Blood (2023) 142 (Supplement 1): 5877.

https://doi.org/10.1182/blood-2023-182976

Published: 2023

Journal Articles

Novel Gene Mutations Associated with Disease-Free Survival in Elderly Patients with Acute Myeloid Leukemia Receiving First-Line Induction-Consolidation with or without Azacitidine Post-Remission Treatment

Blood (2023) 142 (Supplement 1): 6046.

https://doi.org/10.1182/blood-2023-186325

Published: 2023

Journal Articles

10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

Blood (2022) 140 (Supplement 1): 1281–1283.

https://doi.org/10.1182/blood-2022-166544

Published: 2022

Journal Articles

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 6119–6121.

https://doi.org/10.1182/blood-2022-157937

Published: 2022

Journal Articles

Posaconazole at Standard Dose Is Safe and More Effective Than Echinocandins As IFD Prophylaxis in Patients with FLT3 Mutated AML Treated with Midostaurin

Chiara Cattaneo, Francesco Marchesi, Valentina Bonuomo, Nicola S Fracchiolla, Anna Candoni, Marianna Criscuolo, Lucia Prezioso, Crescenza Pasciolla, Maria Ilaria Del Principe, Michelina Dargenio, Giuseppe Tarantini, Maria Enza Mitra, Francesca Farina, Federica Colnaghi, Mariarita Sciumè, Gianpaolo Nadali, Alessandro Busca, Giuseppe Rossi, Livio Pagano

Blood (2021) 138 (Supplement 1): 4381.

https://doi.org/10.1182/blood-2021-149080

Published: 2021

Journal Articles

Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 2359.

https://doi.org/10.1182/blood-2021-147200

Published: 2021

Journal Articles

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Blood (2021) 138 (Supplement 1): 1262.

https://doi.org/10.1182/blood-2021-153028

Published: 2021

Journal Articles

Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

Blood (2021) 138 (Supplement 1): 3373.

https://doi.org/10.1182/blood-2021-149459

Published: 2021

Journal Articles

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Blood (2021) 138 (Supplement 1): 216.

https://doi.org/10.1182/blood-2021-150958

Published: 2021

Journal Articles

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-138371

Published: 2020

NARROW

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Impact of COVID-19 in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Possible Role of the Association to Anti-CD20 Antibody? a Multicentre Seifem Study

Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)

Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study

Gimema Seifem Real-Life Study VS Randomized CPX-351 Registrative Trial for Older Patients with Secondary ACUTE Myeloid Leukemia: An Unanchored Matching-Adjusted Indirect Comparison of Infection Rates and Survival Outcomes

Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol

Novel Gene Mutations Associated with Disease-Free Survival in Elderly Patients with Acute Myeloid Leukemia Receiving First-Line Induction-Consolidation with or without Azacitidine Post-Remission Treatment

10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Posaconazole at Standard Dose Is Safe and More Effective Than Echinocandins As IFD Prophylaxis in Patients with FLT3 Mutated AML Treated with Midostaurin

Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only